Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 27, 2010

Clinical Genomics Snags Colorectal Cancer Biomarkers from Garvan Institute

  • Clinical Genomics and The Garvan Institute of Medical Research entered into a license agreement in relation to novel biomarkers discovered by scientists at the Garvan Institute. Under the terms of the deal, Clinical Genomics obtained worldwide, exclusive rights to Garvan's cancer-associated methylation DNA biomarkers for the diagnosis and/or treatment of colorectal cancer.

    Clinical Genomics intends to expand its colorectal biomarker research program to evaluate these biomarkers. The aim is to develop a diagnostic test utilizing those markers that demonstrate clinical benefit for the early detection of colorectal cancer.

    "Through this strategic licensing agreement with the Garvan Institute, we have complemented our existing technology portfolio and enhanced our ability to develop next-generation products for diagnosing colorectal cancer at the earliest, most treatable stage," states Dr. Lawrence LaPointe, CEO of Clinical Genomics.

    Clinical Genomics was co-founded with Quest Diagnostics in September 2006 to develop, extend, and commercialize molecular markers for colorectal disease. The company works with the Department of Gastroenterology at Flinders Medical Centre, Adelaide, to access specimens for its validation program.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »